Skip to content

Monitoring of Allergic and Asthmatic Symptoms in Patients Taking Dietary Supplements Joalis Bambi Bronchi and Joalis Bambi Analerg

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01684137
Enrollment
100
Registered
2012-09-12
Start date
2012-08-31
Completion date
Unknown
Last updated
2012-09-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Children

Keywords

Food supplements, Asthma bronchiale

Brief summary

Reduction of the total IgE antibody, improved vital capacity and lung volume measured by spirometry. Improving quality of life observed in the visual analogue scale (VAS).

Interventions

DIETARY_SUPPLEMENTJoalis Bambi Bronchi
DIETARY_SUPPLEMENTPlacebo

Sugar pill manufactured to mimic Joalis Bambi Analerg

DIETARY_SUPPLEMENTJoalis Bambi Analerg

Sponsors

DSC Services, s.r.o.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
9 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

* subjects with confirmed Asthma bronchiale I-III. degrees in possible combination with other allergic symptoms treating with classic pharmacological treatment * 9-18 years * signed Infromed Conset

Exclusion criteria

* subjects who have previously used a food suplemts Joalis * subjects with known intolerance or hypersensitivity to the components of food supplements * subjects with alcohol abuse or drugs at the time of recruitment into the study * subjects enrolled in another clinical trial in the last 1 month before enrollment in this study * subjects in a situation which in the opinion of a doctor may interfere with optimal participation in the study or can pose a risk to the subjects * pregnant girls, lactating girls and girls of childbearing age without adequate contraception

Design outcomes

Primary

MeasureTime frame
Reduction of the total IgE (IU/ml) antibody.1 year
Improving of vital capacity measured by spirometry (litre).1 year
Improving of lung volume measured by spirometry (litre).1 year

Secondary

MeasureTime frame
Improving of quality of life observed in the visual analogue scale (VAS).1 year

Other

MeasureTime frame
Asthma bronchiale, age 9-18 year1 year

Countries

Czechia

Contacts

Primary ContactKarel Chroust, RNDr., Ing., PhD..
chroust@dscservices.cz+420 777 826 208

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026